Greenshoe

DGAP-News: Cherry AG: Post-Stabilisation disclosure - partial exercise of the Greenshoe Option

Retrieved on: 
Wednesday, July 28, 2021
Stock market, Financial economics, Initial public offering, Finance, Greenshoe, Options, Money, Security, Exercise, Corporate finance

Disclosure of the partial exercise of the Greenshoe Option in accordance with Article 8 lit.

Key Points: 
  • Disclosure of the partial exercise of the Greenshoe Option in accordance with Article 8 lit.
  • the option granted by the selling shareholder Cherry TopCo S.
  • The Greenshoe Option was exercised by the Stabilisation Manager in the amount of 1,083,430 no-par value ordinary shares of the Issuer.
  • There will be no public offer of the securities in the United States.

Ryan Specialty Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Monday, July 26, 2021
Insurance, Professional services, Financial markets, Financial economics, Initial public offering, Finance, Stock market, Corporate finance, Greenshoe, Stock, Public offering, Subscription, Underwriting, Prospectus

Ryan Specialty Group Holdings, Inc. (Ryan Specialty) today announced that the underwriters of the previously announced initial public offering of 56,918,278 shares of its Class A common stock exercised their option to purchase an additional 8,537,742 shares of Class A common stock from Ryan Specialty at the initial public offering price of $23.50 per share, less underwriting discounts and commissions.

Key Points: 
  • Ryan Specialty Group Holdings, Inc. (Ryan Specialty) today announced that the underwriters of the previously announced initial public offering of 56,918,278 shares of its Class A common stock exercised their option to purchase an additional 8,537,742 shares of Class A common stock from Ryan Specialty at the initial public offering price of $23.50 per share, less underwriting discounts and commissions.
  • Including the exercise of the over-allotment option, Ryan Specialty has issued a total of 65,456,020 shares, for gross proceeds of approximately $1.54 billion before deducting underwriting discounts and commissions.
  • Upon completion of the initial public offering and the consummation of the underwriters option to purchase additional shares and the application of the proceeds therefrom as described in the final prospectus, there will be 109,903,867 shares of Class A common stock outstanding.
  • The shares are listed for trading on the New York Stock Exchange under the symbol RYAN.

Stabilizing Actions and End of Stabilization Period in connection with the Global Offering

Retrieved on: 
Friday, July 23, 2021
Initial public offering, Financial markets, Finance, Financial economics, Stock market, Greenshoe, Prospectus, Immunotherapy, Subscription, Short

There has been no purchase or sale of any Shares on the market for the purpose of price stabilization by the Stabilizing Manager during the stabilization period.

Key Points: 
  • There has been no purchase or sale of any Shares on the market for the purpose of price stabilization by the Stabilizing Manager during the stabilization period.
  • For further details of the full exercise of the Over-allotment Option, please refer to the HUTCHMED announcement dated July 12, 2021.
  • It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
  • Potential investors should read the Prospectus for detailed information about the Company and the Global Offering before deciding whether or not to invest in the Offer Shares.

AzurRx BioPharma Announces $3.0 Million Bought Deal Offering of Common Stock

Retrieved on: 
Thursday, July 22, 2021
Financial markets, Finance, Financial economics, Corporate finance, Stock market, Initial public offering, Actuarial science, Underwriting, Public offering, Stock, Greenshoe, Red herring prospectus

The Company has granted to the underwriter a 30-day option to purchase up to an additional 818,181 shares of common stock at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • The Company has granted to the underwriter a 30-day option to purchase up to an additional 818,181 shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The gross proceeds to AzurRx, before deducting underwriting discounts and commissions and offering expenses and assuming no exercise of the underwriters option to purchase additional common stock, are expected to be approximately $3.0 million.
  • The shares of common stock are being offered by the Company pursuant to a shelf registration statement on Form S-3 (File No.
  • AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical companyspecializingin the development of targeted, non-systemic therapies forgastrointestinal (GI) diseases.

Clover Leaf Capital Corp. Announces Closing of $138.3 Million Initial Public Offering, Including Partial Exercise of Underwriters’ Over-Allotment Option

Retrieved on: 
Thursday, July 22, 2021
Financial markets, Stock market, Finance, Money, NASDAQ, Ticker symbol, Initial public offering, Security, Greenshoe

Miami, FL., July 22, 2021 (GLOBE NEWSWIRE) -- Clover Leaf Capital Corp. (Nasdaq: CLOEU) (Clover Leaf or the Company) today announced the closing of its initial public offering of 13,831,230 units at a price of $10.00 per unit, including 1,331,230 units sold pursuant to the partial exercise of the underwriters over-allotment option, at an offering price of $10.00 per unit.

Key Points: 
  • Miami, FL., July 22, 2021 (GLOBE NEWSWIRE) -- Clover Leaf Capital Corp. (Nasdaq: CLOEU) (Clover Leaf or the Company) today announced the closing of its initial public offering of 13,831,230 units at a price of $10.00 per unit, including 1,331,230 units sold pursuant to the partial exercise of the underwriters over-allotment option, at an offering price of $10.00 per unit.
  • The units commenced trading on the Nasdaq Capital Market (Nasdaq) under the ticker symbol CLOEU on July 20, 2021.
  • A registration statement relating to the securities was declared effective by the Securities and Exchange Commission (SEC) on July 19, 2021.
  • The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

U.S. Century Bank Announces Pricing of Initial Public Offering of Class a Common Stock

Retrieved on: 
Friday, July 23, 2021
Small business, Banking, Professional services, Finance, Financial markets, Financial economics, Finance, Corporate finance, Stock market, Initial public offering, Equity securities, Stock, Underwriting, Preferred stock, Public offering, Greenshoe, Small business, Banking, Professional services, Finance, Financial markets, Financial economics, Finance, Corporate finance, Stock market, Initial public offering, Equity securities, Stock, Underwriting, Preferred stock, Public offering, Greenshoe

U.S. Century Bank (USCB) announced today the pricing of the initial public offering of 4,000,000 shares of its Class A common stock, at a public offering price of $10.00 per share for expected net proceeds to U.S. Century Bank, after deducting the underwriting discount and estimated offering expenses, of approximately $34.0 million.

Key Points: 
  • U.S. Century Bank (USCB) announced today the pricing of the initial public offering of 4,000,000 shares of its Class A common stock, at a public offering price of $10.00 per share for expected net proceeds to U.S. Century Bank, after deducting the underwriting discount and estimated offering expenses, of approximately $34.0 million.
  • U.S. Century Bank has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of its Class A common stock, at the initial public offering price of $10.00 per share, minus the underwriting discount.
  • The exchange offer expired on July 21, 2021 and closed effective as of today, with U.S. Century Bank accepting for exchange approximately $102.8 million in total aggregate liquidation amount of Class C and Class D preferred stock in exchange for Class A common stock, which Class A common stock was issued at the exchange rate established by the initial offering price established in the public offering.
  • Therefore, U.S. Century Bank cautions you not to place undue reliance on U.S. Century Bank's forward-looking information and statements.

IN8bio Launches Proposed Initial Public Offering

Retrieved on: 
Thursday, July 22, 2021
Initial public offering, Financial markets, Finance, Financial economics, Corporate finance, Stock market, Underwriting, Public offering, Greenshoe, Gross spread

In addition, IN8bio expects to grant the underwriter a 30-day option to purchase up to 600,000 additional shares of common stock at the public offering price, less the underwriting discount.

Key Points: 
  • In addition, IN8bio expects to grant the underwriter a 30-day option to purchase up to 600,000 additional shares of common stock at the public offering price, less the underwriting discount.
  • All of the shares to be sold in the proposed offering will be offered by IN8bio.
  • The initial public offering price is expected to be between $10.00 and $12.00 per share.
  • Certain statements herein concerning the Companys future expectations, plans and prospects, including without limitation, the pricing of the Companys proposed initial public offering, may constitute forward looking statements.

TRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 Million

Retrieved on: 
Thursday, July 22, 2021
Financial markets, Finance, Financial economics, Stock market, Corporate finance, Initial public offering, Underwriting, Actuarial science, Stock, Public offering, Greenshoe, Red herring prospectus

In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 589,005 shares of common stock at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 589,005 shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The closing of the public offering is expected to occur on or about July 26, 2021, subject to satisfaction of customary closing conditions.
  • H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.
  • The shares of common stock are being offered pursuant to an effective registration statement on Form S-3 (File No.

Absci Announces Pricing of Initial Public Offering

Retrieved on: 
Thursday, July 22, 2021
Financial markets, Financial economics, Finance, Corporate finance, Initial public offering, Stock market, Underwriting, Stock, Public offering, Greenshoe, Red herring prospectus

VANCOUVER, Wash., July 21, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Absci), the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, today announced the pricing of its initial public offering of 12,500,000 shares of common stock at a public offering price of $16.00 per share.

Key Points: 
  • VANCOUVER, Wash., July 21, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Absci), the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, today announced the pricing of its initial public offering of 12,500,000 shares of common stock at a public offering price of $16.00 per share.
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Absci, are expected to be $200.0 million, excluding any exercise of the underwriters option to purchase additional shares.
  • The offering is expected to close on July 26, 2021, subject to the satisfaction of customary closing conditions.
  • In addition, Absci has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

TRACON Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock

Retrieved on: 
Wednesday, July 21, 2021
Financial markets, Stock market, Finance, Financial economics, Corporate finance, Initial public offering, Actuarial science, Underwriting, Stock, Greenshoe, Red herring prospectus

In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional392,670 shares of common stock at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional392,670 shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on or about July 26, 2021, subject to satisfaction of customary closing conditions.
  • The gross proceeds of the offering are expected to be approximately $10 million, prior to deducting underwriting discounts, commissions and estimated offering expenses and excluding the exercise of the underwriters option to purchase additional shares.
  • The shares of common stock are being offered pursuant to an effective registration statement on Form S-3 (File No.